ArticleFrontiers in microbiology2024
Resurgence of respiratory syncytial virus with dominance of RSV-B during the 2022-2023 season.
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Delineating RSV-A and RSV-B: Epidemiological Patterns, Diagnostics, Clinical Severity, and Preventive Approaches.Journal of medical virology · 2026Review
- Evolutionary dynamics of Respiratory Syncytial Virus in pre-pandemic, pandemic, and post-pandemic periods in Houston, Texas, USA.bioRxiv : the preprint server for biology · 2026Article
- Epidemiology and subtype analysis of respiratory syncytial virus among hospitalized children under five in Isfahan during early 2024.Iranian journal of microbiology · 2026Article
- Impacts of relaxed mask policies on COVID-19 epidemics: a modeling study in South Korea.BMC infectious diseases · 2026Article
- The prevalence and role of human respiratory syncytial virus in pediatric respiratory tract infections: a systematic review and meta-analysis of global data.EClinicalMedicine · 2026Article
- Article
- Monitoring of RSV-A and RSV-B Circulation in Poland Across Three Post-Pandemic Seasons (2022-2025).Viruses · 2026Article
- Prevalence and molecular characteristics of respiratory syncytial virus in hospitalized children in Shenzhen during the COVID-19 pandemic: a retrospective study.Translational pediatrics · 2026Article
- Genomic surveillance of Influenza, SARS-CoV-2, and RSV in patients from Islamabad and Rawalpindi, Pakistan: a 2023-24 perspective.Archives of virology · 2026Article
- Article
- Prevalence and genetic diversity of respiratory syncytial viruses circulating in Bulgaria, 2023-2025.Frontiers in cellular and infection microbiology · 2026Article
- Normalization of Seasonality and Age Distribution of Pediatric RSV Infection Following the Pandemic Disruption in the Netherlands.Open forum infectious diseases · 2026Article
- Genetic diversity and molecular characterization of HRSV-A on the coast of Peru, 2009-2020.Frontiers in microbiology · 2026Article
- Impact of previous SARS-CoV-2 infection on the severity of respiratory syncytial virus infection in hospitalized children.Scientific reports · 2025Article
- Genetic characteristics and epidemiology of influenza and respiratory syncytial viruses associated with acute respiratory infections in Thailand.BMC infectious diseases · 2025Article
- In-Hospital Death and Risk Factors in Adults With Respiratory Syncytial Virus in Spain (2016-2023). A Cross-Sectional Study With Focus on Older Patients.Health science reports · 2025Article
- Article
- Equal Prevalence of Genotypes ON1 and BA of Human Orthopneumovirus in Riyadh, Saudi Arabia, in 2022.Current issues in molecular biology · 2025Article
- Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti-F Monoclonal Antibodies in Panama (2018-2024).Influenza and other respiratory viruses · 2025Article
- Genetic and Epidemiological Insights Into Respiratory Syncytial Virus Infections: A Comparative Study of Hospitalized Versus Community Cases in Portugal (2021-2023).Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) is a common cause of upper and lower respiratory tract infections. This study aimed to explore the prevalence of respiratory syncytial virus (RSV) and other respiratory viruses in Bulgaria, characterize the genetic diversity of RSV strains, and perform amino acid sequence analyses of RSV surface and internal proteins. Methods: Clinical and epidemiological data and nasopharyngeal swabs were prospectively collected from patients with acute respiratory infections between October 2020 and May 2023. Real-time PCR for 13 respiratory viruses, whole-genome sequencing, phylogenetic, and amino acid analyses were performed. Results: This study included three epidemic seasons (2020-2021, 2021-2022, and 2022-2023) from week 40 of the previous year to week 20 of the following year. Of the 3,047 patients examined, 1,813 (59.5%) tested positive for at least one viral respiratory pathogen. RSV was the second most detected virus (10.9%) after SARS-CoV-2 (22%). Coinfections between RSV and other respiratory viruses were detected in 68 cases, including 14 with SARS-CoV-2. After two seasons of low circulation, RSV activity increased significantly during the 2022-2023 season. The detection rates of RSV were 3.2, 6.6, and 13.7% in the first, second, and third seasons, respectively. RSV was the most common virus found in children under 5 years old with bronchiolitis (40%) and pneumonia (24.5%). RSV-B drove the 2022-2023 epidemic. Phylogenetic analysis indicated that the sequenced RSV-B strains belonged to the GB5.0.5a and GB5.0.6a genotypes. Amino acid substitutions in the surface and internal proteins, including the F protein antigenic sites were identified compared to the BA prototype strain. Conclusion: This study revealed a strong resurgence of RSV in the autumn of 2022 after the lifting of anti-COVID-19 measures, the leading role of RSV as a causative agent of serious respiratory illnesses in early childhood, and relatively low genetic diversity in circulating RSV strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.